Part of the difficulty in comparing maraviroc and
Post# of 148190
trding's article perpetuates this mistake:
" (leronlimab) Doesn't block natural activity of ccr5 including no hepatotoxicity causing many others to fail their trial safety metric."
The "LL doesnt interfere with CCR5 function" theme derives from the early days of leronlimab research on HIV. "Not interfereing with CCR5 natural function" was desired to get LL approved for HIV.
All of Patterson's work clearly demonstrates that leronlimab interferes with some aspects of LL natural function, and that is precisely why LL is developing so many indications.